We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock

Delisted

LUMO was delisted on the 11th of December, 2024.

100 hedge funds and large institutions have $486M invested in Lumos Pharma, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 27 increasing their positions, 32 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more capital invested

Capital invested by funds: $296M → $486M (+$190M)

60% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 15

27% more call options, than puts

Call options by funds: $59.5M | Put options by funds: $47M

9% more funds holding

Funds holding: 92100 (+8)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

16% less repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 32

Holders
100
Holders Change
+8
Holders Change %
+8.7%
% of All Funds
2.67%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
24
Increased
27
Reduced
32
Closed
15
Calls
$59.5M
Puts
$47M
Net Calls
+$12.5M
Net Calls Change
-$1.85M
Name Holding Trade Value Shares
Change
Change in
Stake
PFS
51
Prospera Financial Services
Texas
$835K -$165K -556 -19%
CCM
52
Cadence Capital Management
Massachusetts
$752K +$626K +2,102 New
RhumbLine Advisers
53
RhumbLine Advisers
Massachusetts
$725K +$56.8K +191 +10%
BIM
54
Baldwin Investment Management
Pennsylvania
$676K +$165K +556 +42%
CS
55
Credit Suisse
Switzerland
$670K +$28.6K +96 +5%
ANTB
56
AMG National Trust Bank
Colorado
$632K
NFA
57
Nationwide Fund Advisors
Ohio
$599K -$8.04K -27 -2%
DekaBank Deutsche Girozentrale
58
DekaBank Deutsche Girozentrale
Germany
$585K -$42.9K -144 -8%
MLICM
59
Metropolitan Life Insurance Company (MetLife)
New York
$580K +$21.1K +71 +5%
RJA
60
Raymond James & Associates
Florida
$568K -$88.1K -296 -16%
VOYA Investment Management
61
VOYA Investment Management
Georgia
$523K
AIG
62
American International Group
New York
$499K -$32.7K -110 -7%
FAM
63
Fenimore Asset Management
New York
$490K
CAN
64
Cetera Advisor Networks
California
$440K +$364K +1,223 New
Citigroup
65
Citigroup
New York
$427K +$271K +909 +319%
BA
66
BlackRock Advisors
Delaware
$406K -$16.7K -56 -5%
PCC
67
Park Circle Company
Maryland
$398K
TAM
68
Tocqueville Asset Management
New York
$390K +$324K +1,089 New
PAM
69
Paradigm Asset Management
New York
$386K -$314K -1,055 -49%
Federated Hermes
70
Federated Hermes
Pennsylvania
$362K +$301K +1,011 New
UBS AM
71
UBS AM
Illinois
$335K +$279K +937 New
D.E. Shaw & Co
72
D.E. Shaw & Co
New York
$313K -$1.01M -3,387 -79%
Deutsche Bank
73
Deutsche Bank
Germany
$299K -$121K -405 -33%
OC
74
Oppenheimer & Co
New York
$298K +$248K +833 New
CIA
75
Capital Impact Advisors
Massachusetts
$296K

LUMO Hedge Fund Activity: Q4 2014 in Review

100 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q4 2014, worth a combined $486M — up 64% from $296M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new LUMO positions and 15 closed out — a net gain of 9 holders — while 27 added to existing stakes and 32 trimmed.

The largest buyer was BlackRock Institutional Trust, adding an estimated $5.24M. The largest seller was Fidelity Investments, cutting an estimated $37.9M.

  • 100 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q4 2014, up from 92 in Q3 2014.
  • Funds reported $486M of Lumos Pharma, Inc. Common Stock stock for Q4 2014, up 64% quarter-over-quarter.
  • 24 funds opened new Lumos Pharma, Inc. Common Stock positions in Q4 2014 and 15 closed out, a net change of +9 holders.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q4 2014 was BlackRock Institutional Trust, an estimated $5.24M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q4 2014 was Fidelity Investments, an estimated $37.9M sold.

Based on aggregated 13F filings for Q4 2014.